GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carilex Medical Inc (ROCO:7726) » Definitions » EBIT

Carilex Medical (ROCO:7726) EBIT : NT$40.7 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Carilex Medical EBIT?

Carilex Medical's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$15.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$40.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Carilex Medical's annualized ROC % for the quarter that ended in Jun. 2024 was 2.26%. Carilex Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 16.45%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Carilex Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 5.43%.

Carilex Medical EBIT Historical Data

The historical data trend for Carilex Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carilex Medical EBIT Chart

Carilex Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT
67.73 42.88 37.40 58.13

Carilex Medical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial 20.06 17.33 33.30 24.83 15.86

Competitive Comparison of Carilex Medical's EBIT

For the Medical Devices subindustry, Carilex Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carilex Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Carilex Medical's EV-to-EBIT falls into.


Carilex Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$40.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carilex Medical  (ROCO:7726) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Carilex Medical's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=8.876 * ( 1 - 38.57% )/( (271.625 + 209.957)/ 2 )
=5.4525268/240.791
=2.26 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=543.442 - 98.661 - ( 173.156 - max(0, 180.753 - 476.742+173.156))
=271.625

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=513.555 - 111.37 - ( 192.228 - max(0, 182.532 - 452.72+192.228))
=209.957

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Carilex Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=31.72/( ( (31.624 + max(185.423, 0)) + (26.604 + max(142.087, 0)) )/ 2 )
=31.72/( ( 217.047 + 168.691 )/ 2 )
=31.72/192.869
=16.45 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(71.627 + 212.685 + 16.703) - (98.661 + 0 + 16.931)
=185.423

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(50.308 + 194.836 + 13.076) - (111.37 + 0 + 4.763)
=142.087

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Carilex Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=40.687/749.399
=5.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carilex Medical EBIT Related Terms

Thank you for viewing the detailed overview of Carilex Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Carilex Medical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carilex Medical Inc (ROCO:7726) » Definitions » EBIT
Comparable Companies
ROCO:1781 ROCO:4198 ROCO:3373 ROCO:6797 ROCO:6572 ROCO:4183 ROCO:6758 ROCO:6767 ROCO:4188 ROCO:4735 ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE
Traded in Other Exchanges
N/A
Address
No.77, Keji 1st Road, Guishan District, Taoyuan, TWN, 33383
Website
https://www.carilexmedical.com
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.

Carilex Medical Headlines

No Headlines